Institutional members access full text with Ovid®

Anticancer activity of tuftsin-derived T peptide in postoperative residual tumors

An, Yinghonga,b; Li, Linnaa; Yang, Dexuana; Jia, Naa; Xu, Chengwanga; Wang, Qionga; Wang, Shanshana; Yuan, Shoujuna

doi: 10.1097/CAD.0000000000000111
Preclinical Reports

Immune adjuvants have been used in cancer biotherapies to stimulate immune response to tumor cells. Despite their potential as anticancer reagents, there are several impediments to their use in clinical applications. In this study, we aim to modify the existing tuftsin structure and evaluate its antitumor activity in preclinical models. We synthesized a novel tuftsin derivative, namely, the T peptide (TP), by linking four tuftsin peptides, which showed enhanced stability in vivo. We then evaluated its anticancer activity in a postoperative residual tumor model in mice, where we surgically removed most of the primary tumor from the host, a procedure mimicking clinically postoperative patients. Despite the limited effect in intact solid tumors, TP strongly inhibited relapsed growth of residual tumors in postsurgical mice. Surgical resection of tumors accelerated residual tumor growth, but TP slowed down this process significantly. Interestingly, TP showed similar effects in human xenograft residual models. As an immunomodulator, TP could synergize the functions of macrophages, thus inhibiting the growth of cocultured tumor cells in vitro. Furthermore, TP could shift the macrophages to the tumor-suppressive M1 type and mobilize them to produce elevated cytotoxic TNF-α and NO. As a result, TP effectively prolonged the survival time of tumor-resected mice. Using the postoperative residual tumor models, we provide a body of evidence showing the antitumor activity of TP, which causes no obvious toxicity. Our study highlights the potential of TP as a postoperative adjuvant in cancer therapies.

aDepartment of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine

bCenter for Clinical Laboratory, Airforce General Hospital of Chinese PLA, Beijing, People’s Republic of China

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.anti-cancerdrugs.com).

Correspondence to Shoujun Yuan, PhD, Department of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine, No. 27, Taiping Road, Beijing 100850, People’s Republic of China Tel/fax: +86 10 66930271; e-mail: yuansj@nic.bmi.ac.cn

Received December 12, 2013

Accepted March 7, 2014

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins